(3aR,4R,6aR)-4-(azidomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole | 144541-70-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aR,4R,6aR)-4-(azidomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole
• 英文别名: methyl 5-azido-5-deoxy-2,3-O-isopropylidene-D-ribofuranoside；Methyl 2,3-O-isopropylidene-5-azido-D-ribofuranoside；5-azido-5-deoxy-1-O-methyl-2,3-O-(1-methylethylidene)-D-ribofuranoside；methyl 5-azido-5-deoxy-2,3-O-(methylethylidene)-D-ribofuranoside；(3aR,6R,6aR)-6-(azidomethyl)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole
• CAS: 144541-70-8
• 化学式: C₉H₁₅N₃O₄
• 分子量: 229.236
• InChiKey: UBIJKPHBWCBYHF-XDTPYFJJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3aR,4R,6aR)-4-(azidomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole 在 对甲苯磺酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 24.5h， 生成 2-<(2S,3R)-4-azido-2,3-dihydroxybutylidene>-1,3-dithiane
  参考文献：
  名称：

  Moss, William O.; Bradbury, Robert H.; Hales, Neil J., Journal of the Chemical Society. Perkin transactions I, 1992, # 15, p. 1901 - 1906

  摘要：

  DOI：
• 作为产物：
  描述：

  卡培他滨杂质25 在 sodium azide 、 高氯酸 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 (3aR,4R,6aR)-4-(azidomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole
  参考文献：
  名称：

  Carbohydrate Protease Conjugates: Stabilized Proteases for Peptide Synthesis

  摘要：

  The synthesis of oligopeptides using stable carbohydrate protease conjugates (CPCs) was examined in acetonitrile solvent systems. CPC[alpha-chymotrypsin] was used for the preparation of peptides containing histidine, phenylalanine, tyrosine, and tryptophan in the P-1 position in 60-93% yield. The CPC[alpha-chymotrypsin]-catalyzed synthesis of octamer Z-Gly-Gly-Phe-Gly-Gly-Phe-Gly-Gly-OEt from Z-Gly-Gly-Phe-Gly-Gly-Phe-OMe was achieved in 71% yield demonstrating that synthesis was the dominant kinetic process relative to amide hydrolysis. CPC[papain] was used to synthesize peptides containing both hydrophilic and hydrophobic amino acids. The Pt specificity of papain for aromatic residues was utilized for the 2 + 3 coupling of Z-Tyr-Gly-OMe to H2N-Gly-Phe-Leu-OH to generate the leucine enkephalin derivative in 79% yield. Although papain is nonspecific for the hydrolysis of N-benzyloxycarbonyl amino acid methyl esters in aqueous solution, the rates of synthesis for these derivitives with nucleophile leucine tert-butyl ester differed by nearly 2 orders of magnitude. CPC[thermolysin] was used to prepare the aspartame precursor Z-Asp-Phe-OMe in 90% yield. The increased stability of CPCs prepared from periodate-modified poly(2-methacrylamido-2-deoxy-D-glucose), poly(2-methacrylamido-2-deoxy-D-galactcose) and poly(5-methacrylamido-5-deoxy-D-ribose), carbohydrate materials designed to increase the aldehyde concentration in aqueous solution, suggests that the stability of CPCs is directly related to the aldehyde concentration of the carbohydrate material. Periodate oxidation of poly(2-methacrylamido-2-deoxy-D-glucose) followed by covalent attachment to a-chymotrypsin gave a CPC with catalytic activity in potassium phosphate buffer at 90 degrees C for 2 h.

  DOI：

  10.1021/jo00112a049

文献信息

• Orally active adenosine kinase inhibitors
  申请人：Metabasis Therapeutics, Inc.

  公开号：US05763597A1

  公开（公告）日：1998-06-09

  This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to orally active, substituted 5-aryl pyrrolo\x9b2,3-d! pyrimidine and 3-aryl pyrazolo\x9b3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

  这项发明涉及腺苷激酶抑制剂和核苷类似物，具体涉及口服活性的取代5-芳基吡咯并[2,3-d]嘧啶和3-芳基吡唑并[3,4-d]嘧啶核苷类似物，其作为腺苷激酶抑制剂的活性。该发明还涉及这些和其他腺苷激酶抑制剂的制备和使用，用于治疗心血管和脑血管疾病、炎症和其他可以通过增加腺苷局部浓度来调节的疾病。
• Water soluble adenosine kinase inhibitors
  申请人：Gensia Inc.

  公开号：US05726302A1

  公开（公告）日：1998-03-10

  This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to water soluble, aryl substituted 4-amino pyrrolo\x9b2,3-d! pyrimidine and pyrazolo\x9b3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

  这项发明涉及腺苷激酶抑制剂和核苷类似物，具体涉及水溶性、芳基取代的4-氨基吡咯[2,3-d]嘧啶和吡唑[3,4-d]嘧啶核苷类似物，其具有作为腺苷激酶抑制剂的活性。该发明还涉及这些腺苷激酶抑制剂的制备和用途，用于治疗心血管和脑血管疾病、炎症以及其他可以通过增加腺苷局部浓度来调节的疾病。
• Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition, and Antiseizure Activity of 5-Iodotubercidin Analogues
  作者：Bheemarao G. Ugarkar、Jay M. DaRe、Joseph J. Kopcho、Clinton E. Browne、Juergen M. Schanzer、James B. Wiesner、Mark D. Erion

  DOI：10.1021/jm000024g

  日期：2000.7.1

  side effects. Adenosine kinase inhibitors (AKIs) represent an alternative strategy, since AKIs may raise local adenosine levels in a more site- and event-specific manner and thereby elicit the desired pharmacology with a greater therapeutic window. Starting with 5-iodotubercidin (IC50 = 0.026 microM) and 5'-amino-5'-deoxyadenosine (IC50 = 0.17 microM) as lead inhibitors of the isolated human AK, a variety

  腺苷受体激动剂产生多种治疗上有用的药理学。然而，迄今为止，由于剂量限制的副作用，它们未能成功进行临床开发。腺苷激酶抑制剂（AKIs）代表了另一种策略，因为AKIs可以以更多位点和事件特异性的方式提高局部腺苷水平，从而以更大的治疗窗口引发所需的药理作用。从5-碘代小球蛋白（IC50 = 0.026 microM）和5'-氨基-5'-脱氧腺苷（IC50 = 0.17 microM）作为分离的人AK的主要抑制剂开始，各种吡咯并[2,3-d]嘧啶核苷类似物通过使用钠盐介导的糖基化方法将5-取代的4-取代的4-氯吡咯并[2,3-d]嘧啶碱基与核糖类似物偶联来设计和制备。5'-氨基-5' 发现5-溴和5-碘结核菌素的β-脱氧类似物是迄今为止报道的最有效的AKI（IC50S <0.001 microM）。在大鼠最大电击（MES）诱发的癫痫发作试验中，几种有效的AKIs表现出抗惊厥活性。
• C-4' modified adenosine kinase inhibitors
  申请人：Metabasis Therapeutics, Inc.

  公开号：US05763596A1

  公开（公告）日：1998-06-09

  This invention relates to adenosine kinase inhibitors and to nucleoside analogs, C-4' modified pyrrolo\x9b2,3-d!pyrimidine and pyrazolo\x9b3,4-d!pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

  这项发明涉及腺苷激酶抑制剂和核苷类似物，即C-4'修饰的吡咯[2,3-d]嘧啶和吡唑[3,4-d]嘧啶核苷类似物，具有作为腺苷激酶抑制剂的活性。该发明涉及这种类型的核苷类似物，在呋喃糖（糖）基团的C-4'位置具有零个或两个取代基。该发明还涉及这些腺苷激酶抑制剂的制备和用途，用于治疗心血管和脑血管疾病、炎症以及其他可以通过增加腺苷局部浓度来调节的疾病。
• Synthesis and activity of nucleoside-based antiprotozoan compounds
  作者：Huu-Anh Tran、Zhaoyan Zheng、Xianghui Wen、Srinivasan Manivannan、Arnaud Pastor、Marcel Kaiser、Reto Brun、Floyd F. Snyder、Thomas G. Back

  DOI：10.1016/j.bmc.2017.02.016

  日期：2017.4

  (IC50=110nM and SI=1010, while a modified guanosine displayed potent activities against L. donovani (IC50=60nM, SI=2720) and T. brucei (IC50=130nM, SI=1250), as well as moderate activity against T. cruzi (IC50=3.4µM, SI=48). These results provide proof of concept for the nucleoside-based antiprotozoan strategy, as well as potential lead compounds for further optimization and validation.

  寄生虫的原生动物利用挽救途径合成嘌呤并产生必需的活性核苷酸，而哺乳动物则能够从头进行生物合成。这种差异为设计潜在的新抗原生动物化合物提供了机会。基于以下假设制备了一系列47个腺苷类似物，它们在2、6和5'位置有修饰，这是基于这样的假设，即此类化合物可作为原生动物核苷挽救酶的底物，而在哺乳动物细胞中仍然是难降解的。核苷经设计可在被寄生虫裂解为相应的嘌呤碱基后产生有毒代谢物。制备了具有相似目的的三种7-脱氮鸟苷衍生物。所有这些化合物均经过体外抗T. brucei（非洲昏睡病），T。cruzi（恰加斯氏病），L。donovani（利什曼病）和恶性疟原虫（疟疾）。为了确定抗原生动物核苷的治疗选择性指数（SI），还测定了它们对大鼠成肌细胞系的细胞毒性。一种腺苷衍生物被证明对恶性疟原虫高度有效（IC50 = 110nM，SI = 1010），而改良的鸟苷则对杜氏疟原虫（IC50 = 60nM，SI =